Xin Lang Cai Jing·2025-09-10 07:22Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Position - As of June 30, 2025, the company had a market capitalization of 18.767 billion yuan, with a trading volume of 38.1828 million yuan and a turnover rate of 0.24% [1]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Investment Dynamics - The stock has seen a net outflow of 1.0654 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. - The average trading cost of the stock is 11.53 yuan, with the current price approaching a resistance level of 12.80 yuan, indicating potential for upward movement if the resistance is broken [6].